Veradermics (MANE) Common Equity (2024 - 2026)

Veradermics has reported Common Equity for 3 years, with the latest figure at $390.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 743.91% year-over-year to $390.6 million; the trailing twelve-month figure through Mar 2026 stood at $390.6 million (up 743.91% YoY), and the FY2025 full-year result was -$121.0 million, down 149.62% from the prior year.
• Common Equity for Q1 2026 stood at $390.6 million, up from -$121.0 million in the prior quarter.
• The five-year high for Common Equity was $390.6 million in Q1 2026, with the low at -$121.0 million in Q4 2025.
• Historically, Common Equity has averaged $40.1 million across 3 years, with a median of -$54.6 million in 2024.
• Annual changes were most pronounced in 2025 — Common Equity tumbled 149.62% — and 2026, when it soared 743.91%.
• Veradermics' Common Equity stood at -$48.5 million in 2024, then plunged by 149.62% to -$121.0 million in 2025, then soared by 422.81% to $390.6 million in 2026.
• The last three Common Equity figures came in at $390.6 million (Q1 2026), -$121.0 million (Q4 2025), and -$60.7 million (Q1 2025), per Business Quant data.